A series of novel N-((5-(3-chloro-4-nitrophenyl)-1,3,4-oxadiazol-2-yl) carbamothioyl) benzamide derivatives (2a-2h) were synthesized and characterized for their potential antidiabetic properties. The synthesis involved multi-step reactions starting from 3-chloro-4-nitrobenzoic acid, and the final compounds were purified by recrystallization. The structures were confirmed using melting points, TLC, FTIR, 1 H-NMR, 13C-NMR, and LC-MS. In-silico pharmacokinetic analysis using SwissADME indicated favorable drug-likeness properties for the synthesized compounds, particularly those with electron-withdrawing substituents. In-vitro assays demonstrated significant α-amylase and α-glucosidase inhibitory activities, with compounds 2a, 2g, and 2h showing the highest potency (IC50 values: 23.19-28.61 µM for α-amylase and 23.25-28.25 µM for α-glucosidase), comparable to the standard drug acarbose. The presence of electron-withdrawing groups enhanced the inhibitory effects, while electron-donating groups reduced efficacy. These findings suggest that the synthesized compounds, particularly 2a, 2g, and 2h, hold promise as effective antidiabetic agents.